For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The purpose of this study is to help researchers to better understand the effect of giving two oral medications in patients with mantle cell lymphoma (MCL) who are planning to receive standard of care CAR-T cell therapy.
This study will help researchers to better understand if these two medications make things better or worse than the usual approach alone (CAR-T cell therapy).
The purpose of this study is to test the safety of a CAR-T (chimeric antigen receptor T cell) therapy. This study tests different doses of the new cell therapy in alveolar soft part sarcoma, renal cancer and breast cancer tumours to see which dose is safest for people.
The purpose of this study is to test the good and bad effects of a combination of new drugs on you and your advanced ovarian cancer for which platinum based chemotherapy is no longer an option.
The purpose of this study is to follow (monitor) your disease, by testing tumour tissue and blood samples to learn more about your cancer and how it responds while you are receiving standard of care treatment with a CDK inhibitor with endocrine therapy.
This trial/study consists of a number of independent studies or “substudies”, each of which is testing a different drug or combination of drugs.
The purpose of the study is to see if DNA abnormalities in your cancer or “biomarkers” can help predict how certain cancers may respond to certain treatments.
The first part of this trial uses biomarker testing to identify which substudy, and therefore which treatment, patients will be assigned to.
